Hope Rugo, Professor of Medicine at the University of California San Francisco, shared a post on X:
“Sara Hurvitz presented the fascinating and important data from Victoria-1. The PIK3CA/mTOR IV inhibitor gedatolisib markedly increased PFS with palbo (and without) comp to fulv alone in the wt population. 19% grade 3 stomatitis. 3 of 4 weekly IV therapy.”
Follow the latest ESMO 2025 news on OncoDaily.
